Alnylam Pharmaceuticals Faces Sharp Market Reversal as Amvuttra Sales Miss and Guidance Cut Trigger 30% Stock Plunge
Cambridge, MA – Alnylam Pharmaceuticals, a pioneering force in RNA interference (RNAi) therapeutics, experienced a...
Knowledge and News for the Global Fight Against Cancer.
Cambridge, MA – Alnylam Pharmaceuticals, a pioneering force in RNA interference (RNAi) therapeutics, experienced a...
In a pivotal decision that could redefine treatment pathways for a challenging subset of melanoma...
A federal lawsuit filed in California has cast a significant shadow over Hims & Hers,...
Vertex Pharmaceuticals, a biopharmaceutical giant predominantly known for its transformative cystic fibrosis treatments, has officially...
Despite announcing positive results from a pivotal Phase 2b study for its experimental schizophrenia medicine...
In a closely watched decision that underscores the complex and often contentious landscape of rare...
The dynamic landscape of biotechnology witnessed a significant strategic shift this week as two burgeoning...
The intricate journey of bringing scientific breakthroughs from the laboratory to patients worldwide is fraught...
Sarepta Therapeutics, a biopharmaceutical company at the forefront of genetic medicine for rare diseases, has...
The integration and evolution of artificial intelligence within the U.S. Food and Drug Administration (FDA)...